BGA
GNMX

Belmont Global Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Belmont Global Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,000
Closed -$111K – 89
2016
Q2 		$111K Buy
+20,000
New +$105K 0.11% 63
2016
Q1 		– Sell
-65,000
Closed -$391K – 95
2015
Q4 		$391K Sell
65,000
-90,000
-58% -$611K 0.51% 54
2015
Q3 		$1.21M Buy
155,000
+118,800
+328% +$921K 2.06% 12
2015
Q2 		$222K Buy
36,200
+6,200
+21% +$48K 0.25% 90
2015
Q1 		$242K Buy
30,000
+10,000
+50% +$75.4K 0.25% 72
2014
Q4 		$101K Sell
20,000
-143,347
-88% -$708K 0.1% 107
2014
Q3 		$848K Sell
163,347
-176,653
-52% -$1.14M 0.66% 49
2014
Q2 		$2.64M Hold
340,000
– – 1.91% 12
2014
Q1 		$2.37M Buy
340,000
+10,000
+3% +$78.1K 1.99% 13
2013
Q4 		$1.98M Buy
+330,000
New +$2.16M 1.6% 15

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Belmont Global Advisors's GNMX Position: Q3 2016 in Review

Belmont Global Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2016, closing a stake of 20,000 shares — an estimated $111K sold.

Belmont Global Advisors first reported a position in GNMX in Q4 2013 and held it in 10 quarters. The position peaked at $2.64M in Q2 2014. 68 funds tracked by Wall St. Rank hold GNMX as of Q3 2016.

  • Belmont Global Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q3 2016 after selling out during the quarter.
  • Belmont Global Advisors sold 20,000 Aevi Genomic Medicine Inc shares in Q3 2016, an estimated $111K.
  • Belmont Global Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2013 and held it in 10 quarters.
  • Belmont Global Advisors's Aevi Genomic Medicine Inc position peaked at $2.64M in Q2 2014.
  • 68 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.